JOHN BALLANTYNE, FORMER BIOTECHNOLOGY EXECUTIVE, JOINS THE GLUCOTRACK BOARD OF DIRECTORS
Glucotrack Inc. (Nasdaq: GCTK), a medical technology company focused on developing novel technologies for diabetes management, has appointed John Ballantyne, PhD, to its Board of Directors. Ballantyne brings over 20 years of experience from Aldevron, a global biotechnology contract development and manufacturing organization he co-founded. As former Chief Science Officer at Aldevron, Ballantyne has extensive experience in healthcare research, innovation, and strategic growth.
Paul Goode, PhD, President and CEO of Glucotrack, expressed confidence that Ballantyne's expertise will be invaluable as the company expands and moves towards commercializing its novel continuous blood glucose monitoring (CBGM) technology. Ballantyne, who holds a Doctorate in Pharmaceutical Sciences, has developed relationships across various biotechnology sectors through investments and advisory roles.
Glucotrack Inc. (Nasdaq: GCTK), un'azienda di tecnologia medica focalizzata sullo sviluppo di tecnologie innovative per la gestione del diabete, ha nominato John Ballantyne, PhD, nel suo Consiglio di Amministrazione. Ballantyne porta con sé oltre 20 anni di esperienza da Aldevron, un'organizzazione globale di sviluppo e produzione di biotecnologie che ha co-fondato. Come ex Chief Science Officer di Aldevron, Ballantyne ha una vasta esperienza in ricerca sanitaria, innovazione e crescita strategica.
Paul Goode, PhD, Presidente e CEO di Glucotrack, ha espresso fiducia nel fatto che l'expertise di Ballantyne sarà fondamentale mentre l'azienda si espande e si avvicina a commercializzare la sua innovativa tecnologia di monitoraggio continuo della glicemia (CBGM). Ballantyne, che detiene un Dottorato in Scienze Farmaceutiche, ha sviluppato relazioni in vari settori della biotecnologia attraverso investimenti e ruoli di consulenza.
Glucotrack Inc. (Nasdaq: GCTK), una empresa de tecnología médica centrada en el desarrollo de tecnologías novedosas para la gestión de la diabetes, ha nombrado a John Ballantyne, PhD, en su Junta Directiva. Ballantyne aporta más de 20 años de experiencia de Aldevron, una organización global de desarrollo y fabricación de biotecnología que co-fundó. Como ex Director Científico de Aldevron, Ballantyne tiene una amplia experiencia en investigación en salud, innovación y crecimiento estratégico.
Paul Goode, PhD, Presidente y CEO de Glucotrack, expresó su confianza en que la experiencia de Ballantyne será invaluable a medida que la empresa se expande y se acerca a comercializar su innovadora tecnología de monitoreo continuo de glucosa en sangre (CBGM). Ballantyne, que posee un Doctorado en Ciencias Farmacéuticas, ha desarrollado relaciones en varios sectores de biotecnología a través de inversiones y roles de asesoría.
글루코트랙 Inc. (Nasdaq: GCTK)는 당뇨병 관리를 위한 혁신적인 기술 개발에 중점을 둔 의료 기술 회사로, 존 발란타인(John Ballantyne) 박사를 이사회에 임명했습니다. 발란타인은 자신이 공동 설립한 글로벌 생명공학 계약 개발 및 제조 기관인 Aldevron에서 20년 이상의 경력을 가지고 있습니다. Aldevron의 전 Chief Science Officer로서, 발란타인은 의료 연구, 혁신 및 전략적 성장에 대한 폭넓은 경험을 보유하고 있습니다.
글루코트랙의 사장 겸 CEO인 폴 굿(Paul Goode) 박사는 발란타인의 전문성이 회사가 성장하고 혁신적인 지속 혈당 모니터링(CBGM) 기술을 상용화하는 과정에서 매우 중요할 것이라고 확신했습니다. 제약 과학 박사 학위를 보유한 발란타인은 투자 및 자문 역할을 통해 다양한 생명공학 분야에서 관계를 발전시켜왔습니다.
Glucotrack Inc. (Nasdaq: GCTK), une entreprise de technologie médicale axée sur le développement de technologies innovantes pour la gestion du diabète, a nommé John Ballantyne, PhD, au sein de son Conseil d'Administration. Ballantyne apporte plus de 20 ans d'expérience d'Aldevron, une organisation mondiale de développement et de fabrication en biotechnologie qu'il a co-fondée. En tant qu'ancien directeur scientifique d'Aldevron, Ballantyne possède une vaste expérience en recherche en santé, innovation et croissance stratégique.
Paul Goode, PhD, Président et CEO de Glucotrack, a exprimé sa confiance dans le fait que l'expertise de Ballantyne sera inestimable alors que l'entreprise se développe et se rapproche de la commercialisation de sa technologie innovante de surveillance continue de la glycémie (CBGM). Ballantyne, qui détient un doctorat en sciences pharmaceutiques, a développé des relations dans divers secteurs de la biotechnologie par le biais d'investissements et de rôles de conseil.
Glucotrack Inc. (Nasdaq: GCTK), ein Medizintechnikunternehmen, das sich auf die Entwicklung neuartiger Technologien für das Diabetesmanagement konzentriert, hat John Ballantyne, PhD, in seinen Vorstand berufen. Ballantyne bringt über 20 Jahre Erfahrung von Aldevron, einer globalen Biotechnologie-Dienstleistungs- und Produktionsorganisation, die er mitbegründet hat. Als ehemaliger Chief Science Officer von Aldevron hat Ballantyne umfassende Erfahrungen in der Gesundheitsforschung, Innovation und strategischem Wachstum.
Paul Goode, PhD, Präsident und CEO von Glucotrack, äußerte sich zuversichtlich, dass Ballantynes Fachkenntnisse von unschätzbarem Wert sein werden, während das Unternehmen wächst und sich dem der Kommerzialisierung seiner neuartigen Technologie zur kontinuierlichen Blutzuckerüberwachung (CBGM) nähert. Ballantyne, der einen Doktortitel in pharmazeutischen Wissenschaften besitzt, hat durch Investitionen und Beratungsrollen Beziehungen in verschiedenen Biotechnologiesektoren aufgebaut.
- Appointment of John Ballantyne, an experienced biotech executive, to the Board of Directors
- Ballantyne brings 20+ years of experience in healthcare research, innovation, and strategic growth
- Potential for accelerated commercialization of Glucotrack's continuous blood glucose monitoring technology
- None.
Biotech veteran joins Glucotrack’s Board to support bringing novel continuous blood glucose monitoring technology to people with diabetes
Rutherford, NJ, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced the appointment of John Ballantyne, PhD to its Board of Directors, effective immediately.
“We are pleased to welcome John, who has been a long-standing supporter of the Company, to our Board of Directors," said Paul Goode, PhD, President and CEO of Glucotrack. "An entrepreneur himself, John brings extensive experience in driving healthcare research and innovation, strategic growth, and other key business functions that will be invaluable as we continue to expand our organization and move towards commercializing our novel technology."
Mr. Ballantyne brings over 20 years of experience on the executive team at the global biotechnology contract development and manufacturing organization, Aldevron. He co-founded the company in 1998 and served as its Chief Science Officer through its acquisition by Danaher, and until his retirement. A leader in advancing biological science, Aldevron’s custom development and manufacturing services have provided scientists around the world with the essential components to accelerate research within their laboratories for groundbreaking science and breakthrough discoveries.
Due to the company’s significant presence in the biotechnology sector, Mr. Ballantyne has developed relationships across a continuum of focus areas maintained through investments, Board and Scientific Advisory Board roles and co-founding of multiple companies. Mr. Ballantyne holds undergraduate degrees in Pharmacy from the Central Institute of Technology (Heretaunga, NZ) and University of Otago (Dunedin, NZ) and his Doctorate in Pharmaceutical Sciences from North Dakota State University (Fargo, ND).
“I am excited to be joining the Board of a such an innovative medical technology company,” said Mr. Ballantyne. “Glucotrack’s continuous blood glucose monitor (CBGM) will really make a difference in the lives of people with diabetes. I look forward to joining the Board and helping the organization to continue to advance its mission, achieve its strategic milestones and drive toward success.”
For more information about Glucotrack’s CBGM, visit glucotrack.com.
# # #
About Glucotrack, Inc.
Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes.
Glucotrack’s CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 2+ years, no on-body wearable component and with minimal calibration. For more information, please visit http://www.glucotrack.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “believe”, “expect”, “plan” and “will” are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Readers are cautioned that certain important factors may affect Glucotrack’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Glucotrack’s results include, but are not limited to, the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including U.S. Food and Drug Administration approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to Glucotrack’s future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Glucotrack’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2023 as filed with the SEC on March 28, 2024.
Contacts:
Investor Relations:
investors@glucotrack.com
Media:
GlucotrackPR@icrinc.com
FAQ
Who is John Ballantyne and why was he appointed to Glucotrack's (GCTK) Board of Directors?
What is Glucotrack's (GCTK) main product focus?
How might John Ballantyne's appointment impact Glucotrack's (GCTK) future plans?
What is John Ballantyne's educational background?
